Compare Corning Incorporated (GLW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GLW trades at $165.69, up 5.41% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $15.63B in 2025, with net income surging to $1.60B. The stock is supported by AI-driven optical demand and analyst optimism, though valuation multiples like a P/E of 76.35 appear elevated. Recent news highlights partnerships with major tech firms and a strategic focus on photonics expansion.

The outlook for GLW is positive, driven by AI infrastructure growth and a $10B photonics goal, but risks include high valuation sensitivity and execution challenges. Analysts project a 16.6% upside to the $193.33 consensus target, with 57% recommending buy. Investors should weigh robust fundamentals against premium pricing and competitive pressures in the semiconductor supply chain.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.